Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« How Much to Develop a Drug? An Update. | Main | Druggability: A Philosophical Investigation »

August 13, 2013

Sanofi in China

Email This Entry

Posted by Derek

Now Sanofi is tangled up in trouble in China. The last few days have brought news of a wide-ranging investigation into payments to hospitals and medical workers, similar to what GlaxoSmithKline has been accused of.

And I don't have much reason to doubt either story, because (as this BBC story details) payments of this sort are rife. I would also note that, according to the AP, the Chinese government "is investigating production costs at 60 Chinese and foreign pharmaceutical manufacturers, according to state media, possible as a prelude to revising state-imposed price caps on key medications."

A system where everyone is in violation of the law has a lot of advantages - if you're the government. Retribution, when it's needed, is always at hand, because all you have to do is threaten to enforce what's already on the books. And lest someone think that I'm just beating away at the Chinese situation, the same applies to the US (on what I hope is a lower level). Here's economist Tyler Cowen, from the Marginal Revolution blog, on that very subject:

Faced with the evidence of an non-intentional crime, most prosecutors, of course, would use their discretion and not threaten imprisonment. Evidence and discretion, however, are precisely the point. Today, no one is innocent and thus our freedom is maintained only by the high cost of evidence and the prosecutor’s discretion.

The GSK and Sanofi allegations are, of course, all about intentional acts. But prosecuting them is very much up to the discretion of the Chinese authorities. If they're trying to root out corruption in their health care system, more power to them, because that's a worthy cause. But if they're just putting the squeeze on people long enough to bargain with them, only to let things return to the status quo ante after concessions have been extracted, then I have another opinion. Cynically, that's just what I expect to happen. After all, one might need to charge these companies with bribery again at some point. The Chinese authorities - authorities in general, all over the world - are not in the habit of putting down useful weapons and walking away from them.

Comments (14) + TrackBacks (0) | Category: Business and Markets | The Dark Side


COMMENTS

1. Anonymous on August 13, 2013 7:50 AM writes...

All good companies behave bad after they do business in China.

Permalink to Comment

2. counterclokwise swirl on August 13, 2013 9:52 AM writes...

this looks like business as usual in China for pharma. who is next?

Permalink to Comment

3. Anchor on August 13, 2013 9:59 AM writes...

They all are breaking bad! Big pharmaceutical companies knew all along that they can work through in China simply by bribing the communist apparatchik at all levels! That is the only way the communists operate and reach the top echelons of power! So they were all willing to be bribed and now the thug and slimy Chinese officials are claiming they are being bribed?

Permalink to Comment

4. Anon on August 13, 2013 10:04 AM writes...

These companies put themselves in this boat. Unfortunately that just means the costs of R&D+profit margin will be made up here in the US as China/India/Europe are able to barter on pricing.

What will likely be done in China is present companies with a couple of options

1. Compulsory Licencing: China will legally allow their domestics to produce the drug and turn a profit
2. Blind eye Licensing: China will allow their domestics to produce the drug and choose not to prosecute them (let them steal it)
3. China will exchange reduced prosecution related to current events for lower drug pricing.

They are essentially stocking up on blackmail options.
What ever the case, the Chinese economy stands to benefit. Suddenly "access" to this large market doesn't seem so lucrative when your margins per drug sold fall out.
China will likely try to keep this dance going as long as possible (if big pharma pulls out now, it will be harder for them to get their hands on "western" medications 10 years from now).
The example I think of is from the movie E.T. when a genius martian is lured by simple candy pieces.

Permalink to Comment

5. anonymous 2 on August 13, 2013 10:11 AM writes...

With these things it's never clear to me who's wrongdoing I should be concerned about. There's a big moral difference between paying somebody off to look the other way, and paying somebody off to get them to do their effing job or to let you do yours. In the former case the crime is bribery, but in the latter case the crime is really extortion, and coming down on the briber is just blaming the victim.

Permalink to Comment

6. NoDrugsNoJobs on August 13, 2013 10:27 AM writes...

Either every pharma company and its many people are truly bad and that's why we see repeated allegations and settlements or the laws are so compex and subject to interpretation that any given company could be taken on at some point and for some thing and simply cannot afford the grief and uncertainty inherent with fighting back. More likely a combination of both. I am skeptical of all these huge financial settlements in the US with no criminal prosecitions. The bar to proving criminal behavior is very real and people will definitely fight back, forcing the government to prove its case before jury. They seem to prefer taking the easy money and running. Somewhat akin to the criminal forfeiture laws where we see the government confiscating property and then not bringing a criminal case at all or even losing the criminal case. Guess what, they most often still keep the property - how cool is that!

Permalink to Comment

7. anon too on August 13, 2013 10:36 AM writes...

Guess they didn't learn from GSK.

On second throught, maybe they did!

Permalink to Comment

8. MTK on August 13, 2013 10:46 AM writes...

Is the Chinese government cracking down on the bribe takers as much as the bribe makers?

The stories linked cite specific numbers of hospitals and doctors which would seem to indicate they know who was offered and accepted these bribes, yet the stories seem to be centered on the bribers, not the bribees.

It takes two to tango here.

Permalink to Comment

9. Hap on August 13, 2013 11:25 AM writes...

But the other tangoers don't have what the Chinese government wants.

If they were concerned about integrity and government function, the bribeable functionaries should be the primary targets - they were violating their duties to their country and their employers. However, it may also be possible that they don't want to make the corruption in government an issue of discussion - it's easier to blame the crooked foreigners for corruption than your countrymen/women who sold you out, and it is an easier story for those in power to deal with. They might deal with their own crooks in private, so that their corruption isn't seen at all rather than being seen as a failure of the government.

It might still be a shakedown of (foreign) pharma, but it might also be that the government is trying to spin the corruption in a way that doesn't hurt their image.

Permalink to Comment

10. Anonymous on August 13, 2013 11:33 AM writes...

Pharma should record every interaction with every chinese doctor and official, to prove whether it is bribery or extortion, unless of course pharma has something to hide?

Permalink to Comment

11. pete on August 13, 2013 11:34 AM writes...

We patients in the West can be comforted in the knowledge that a portion of what we pay for our drugs helps support needy Chinese & Indian
bureaucrats.

Permalink to Comment

12. Big Tuna on August 13, 2013 11:59 AM writes...

@11,

That should read "we patients in the U.S.".

We are the only country with "free market" pricing for drugs, :-).

Permalink to Comment

13. pete on August 13, 2013 12:55 PM writes...

@9 Hap
Going with your point, I'd also note commentary* around the Shanghai/GSK revelations, suggesting the highly public accusations of non-native Pharmas are, in part, seeking to deflect blame for shortcomings in extending more equitable healthcare throughout China.

* http://business.time.com/2013/07/31/glaxo-case-shines-light-on-chinas-medical-bribery/

@12 BT
yup, that's probably more accurate

Permalink to Comment

14. Anonymous on August 13, 2013 2:01 PM writes...

Guess they do not have code of conduct training

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .